Abstract:Background: A hybrid molecule of different biologically active substances can improve affinity and efficiency compared to a standard drug. Hence based on this fact, we predict that a combination of fluorine, oxadiazole, sulfur, etc., may enhance α-glucosidase inhibition activity compared to a standard drug. Methods: A series of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives (2a-2i) were synthesized and characterized using spectroscopic techniques such as 1HNMR and LC-MS. In order to evaluate its bioactivity, in vitro α-amylase and α-glycosidase inhibitory activity were performed. In vivo study was carried using a genetic model, Drosophila melanogaster, for assessing the antihyperglycemic effects. Results: The compounds 2a-2i demonstrated α-amylase inhibitory activity in the range of IC50 = 40.00-80.00 μg/ml as compare to standard acarbose (IC50 = 34.71 μg/ml). Compounds 2a-2i demonstrated α-glucosidase inhibitory activity in the range of IC50 = 46.01-81.65 μg/ml as compared to standard acarbose (IC50 = 34.72 μg/ml). Docking studies on a target protein, N-terminal subunit of human Maltase-glucoamylase (PDB:2QMJ) was carried and the compounds were found to dock into the active site of the enzyme (Fig. 1). The predicted binding energies of the compounds were calculated. The in vitro studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. Whereas in vivo study indicates that 2b, 2g, and 2i could lower glucose levels in the Drosophila, but then 17-30% reduced capacity than acarbose and may be overcome by adjusting their dosage. Conclusions: The in vitro and in vivo studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. This study has recognized that compounds like 2b, 2g, and 2i may be considered potential candidates for further developing a novel class of antidiabetic agents.

Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin–chrysin as a potent α-glucosidase inhibitor

Chemical Synthesis and Preliminary Biological Evaluation of C-6-O-methyl-1-deoxynojirimycin As a Potent Α-Glucosidase Inhibitor

Analogues of xanthones--Chalcones and bis-chalcones as α-glucosidase inhibitors and anti-diabetes candidates.

ChemInform Abstract: Synthesis and Biological Activity of Novel Deoxynojirimycin Derivatives As Potent Α‐glucosidase Inhibitors.

Synthesis, nitric oxide release, and α-glucosidase inhibition of nitric oxide donating apigenin and chrysin derivatives.

Synthesis and Hypoglycemic Effect of N-[(3-(4-ethoxybenzyl)-4-chlorophenyl]-1-deoxynojirimycin

Synthesis and Biological Activity of Novel Deoxynojirimycin Derivatives As Potent Alpha-Glucosidase Inhibitors

Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors

A New Potent Inhibitor Against Α-Glucosidase Based on an in Vitro Enzymatic Synthesis Approach

Synthesis, in vitro α-glucosidase inhibitory activity and docking studies of novel chromone-isatin derivatives.

Design, Synthesis, and Activity Evaluation of Novel N-benzyl Deoxynojirimycin Derivatives for Use as α-Glucosidase Inhibitors

Synthesis of the chromone‐thiosemicarbazone scaffold as promising α‐glucosidase inhibitors: An in vitro and in silico approach toward antidiabetic drug design

Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting α‐glucosidase

Synthesis and Evaluation of the Α-Glucosidase Inhibitory Activity of 3-[4-(phenylsulfonamido)benzoyl]-2h-1-benzopyran-2-one Derivatives

Synthesis, biological evaluation and action mechanism of 7H-[1,2,4] triazolo [3,4-b] [1,3,4] thiadiazine-phenylhydrazone derivatives as α-glucosidase inhibitors

Xanthone Sulfonamide Derivatives-A Novel Series of Α-Glucosidase Inhibitors with Different Inhibitory Types

Selective synthesis of 3-deoxy-5-hydroxy-1-amino-carbasugars as potential α-glucosidase inhibitors

Synthesis, Molecular Docking and Α-Glucosidase Inhibition of 2-((5,6-Diphenyl-1,2,4-triazin-3-yl)thio)-n-arylacetamides.

Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors

[Synthesis, Biological Activity and Molecular Docking Research of N-{[(4-oxo-thiochroman-3-yl)phenyl]-methyl}acetamide Derivatives As Α-Glucosidase Inhibitors].

Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and Α-Glucosidase As Potential Therapeutic Agents Against Diabetes Mellitus and Its Complications.